308 related articles for article (PubMed ID: 10340540)
21. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.
Kaumann AJ; Galindo-Tovar A; Escudero E; Vargas ML
Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):421-30. PubMed ID: 19693491
[TBL] [Abstract][Full Text] [Related]
22. Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11.
Ahmad M; Abdel-Wahab YH; Tate R; Flatt PR; Pyne NJ; Furman BL
Br J Pharmacol; 2000 Mar; 129(6):1228-34. PubMed ID: 10725272
[TBL] [Abstract][Full Text] [Related]
23. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat.
van Staveren WC ; Markerink-van Ittersum M ; Steinbusch HW; de Vente J
Brain Res; 2001 Jan; 888(2):275-286. PubMed ID: 11150485
[TBL] [Abstract][Full Text] [Related]
24. Rolipram, a selective inhibitor of phosphodiesterase type 4, pronouncedly enhanced the forskolin-induced promotion of dopamine biosynthesis in primary cultured rat mesencephalic neurons.
Yamashita N; Miyashiro M; Baba J; Sawa A
Jpn J Pharmacol; 1997 Sep; 75(1):91-5. PubMed ID: 9334890
[TBL] [Abstract][Full Text] [Related]
25. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.
Kenk M; Greene M; Thackeray J; deKemp RA; Lortie M; Thorn S; Beanlands RS; DaSilva JN
Nucl Med Biol; 2007 Jan; 34(1):71-7. PubMed ID: 17210463
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
Whalen MM; Crews JD
Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
[TBL] [Abstract][Full Text] [Related]
27. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Au BT; Teixeira MM; Collins PD; Williams TJ
Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
[TBL] [Abstract][Full Text] [Related]
28. The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea-pig peritoneal macrophages.
Turner NC; Wood LJ; Burns FM; Gueremy T; Souness JE
Br J Pharmacol; 1993 Apr; 108(4):876-83. PubMed ID: 8387385
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta.
Lugnier C; Schoeffter P; Le Bec A; Strouthou E; Stoclet JC
Biochem Pharmacol; 1986 May; 35(10):1743-51. PubMed ID: 2423089
[TBL] [Abstract][Full Text] [Related]
30. Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.
Grous M; Barnette M
Br J Pharmacol; 1994 Jan; 111(1):259-63. PubMed ID: 7516803
[TBL] [Abstract][Full Text] [Related]
31. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
Qiu Y; Kraft P; Lombardi E; Clancy J
J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
[TBL] [Abstract][Full Text] [Related]
32. Assessing the emetic potential of PDE4 inhibitors in rats.
Robichaud A; Savoie C; Stamatiou PB; Lachance N; Jolicoeur P; Rasori R; Chan CC
Br J Pharmacol; 2002 Jan; 135(1):113-8. PubMed ID: 11786486
[TBL] [Abstract][Full Text] [Related]
33. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Beierwaltes WH
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
[TBL] [Abstract][Full Text] [Related]
34. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
Ellis JL; Conanan ND
J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
Marivet MC; Bourguignon JJ; Lugnier C; Mann A; Stoclet JC; Wermuth CG
J Med Chem; 1989 Jul; 32(7):1450-7. PubMed ID: 2544722
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig.
Turner NC; Dolan JS; Grimsditch D; Lamb J; Worby A; Murray KJ; Coates WJ; Warrington BH
Br J Pharmacol; 1994 Apr; 111(4):1198-204. PubMed ID: 8032606
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells.
Ashikaga T; Strada SJ; Thompson WJ
Biochem Pharmacol; 1997 Nov; 54(10):1071-9. PubMed ID: 9464449
[TBL] [Abstract][Full Text] [Related]
39. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]